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Abstract
Polycomb group (PcG) proteins are crucial for neural cancer stem cell (NCSC) self-renewal. However, the relative
expression levels of PcG genes in different subtypes of brain tumors, their prognostic role and their effects on cel-
lular pathways have not been investigated. For this purpose, we queried the Oncomine database and found that 4
PcG genes (EZH2, RBBP7, SUZ12, YY1) are specifically expressed in brain tumors. EZH2 expression increases with
tumor grade in adult and pediatric brain tumors, and is a poor prognostic factor. In glioblastoma, EZH2 inhibits dif-
ferentiation, and activates cancer-, cell cycle- and cellular movement-related genes. In keeping with previously pub-
lished data, our results suggest that EZH2 is both a prognostic factor and a promising therapy target in brain
tumors.
Findings
Central Nervous System (CNS) tumors occur at each
stage of life, and are therefore classified as embryonal,
pediatric and adult cancers [1-3]. Treatment and prog-
nosis are dependent on tumor histology. For pediatric
and adult CNS cancers, tumor grade is the main prog-
nostic factor [1,3].
Due to the lack of effective therapies for aggressive
CNS tumors, the identification of new targets and prog-
nostic indicators is warranted. Recent evidence shows
that, in addition to genetic changes, CNS tumors are
driven by epigenetic alterations, namely DNA methyla-
tion and histone post-translational modifications [4].
Polycomb group (PcG) genes are epigenetic effectors
involved in CNS development and cancer progression
[5]. PcG proteins are organized in polycomb repressive
complexes (PRCs). During development, PRCs catalyze
histone post-translational modifications and gene silen-
cing. The best characterized complexes are PRC1 and
PRC2. The latter mediates histone H3K27 methylation.
PRC1 binds to this chromatin modification and catalyzes
histone H2A ubiquitylation. PRCs silence lineage-speci-
fic genes in embryonic and adult stem cells (SCs) [5].
During brain development, PRCs are expressed in a
time- and region-specific manner, thereby orchestrating
SC proliferation and differentiation [6]. Each PRC iso-
form targets a different set of loci. This combinatorial
complexity affects the subtle balance between SC self-
renewal and differentiation [5].
Recent evidence indicates that most CNS tumors are
driven by a small population of CD133+ neural cancer
stem cells (NCSC) [7]. These cells are resistant to con-
ventional chemotherapy [8,9] and are the only cells able
to initiate a tumor when injected into immunocompro-
mised mice [7]. In adition, CD133 is up-regulated in
high grade CNS tumors, and is a poor prognostic indi-
cator [10]. Targeting NCSCs could eradicate CNS
tumors [11,12]. However, most data in favor of the
NCSC hypothesis are derived from mouse and in vitro
studies. The role of NCSC in the clinical setting is still
elusive.
For their function in SC biology and cancer [5], PcG
genes are obvious candidates for NCSC-specific targeted
therapy. PcG targets are specifically silenced in brain
tumors [13]. and the PRC2 member EZH2 may be over-
xpressed in gliomas [14]. In addition, BMI1 copy num-
ber alteration is frequent in human gliomas [15]. BMI1
is a PRC1 component, essential for NCSC self-renewal
and tumorigenicity [16]. PcG genes are also involved in
CD133+ glioma SC radioresistance [17].
In the present paper, we queried the Oncomine data-
base to systematically assess relative gene expression
levels of PcG genes in CNS tumors. Gene expression
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data from embryonic, pediatric and adult brain tumors
were collected from Oncomine database http://www.
oncomine.com. Data were from 34 independent studies.
We investigated gene expression profile of 21 PcG
genes: Pc, PH, RING and PSC homologs (PRC1); EED,
EZH2, SUZ12 (PRC2); YY (1 and 2), SCML1, SIRT,
L3MBTL2, RBBP. These genes have been selected based
on previously published lists [18,19]. We compared gene
expression in normal brain vs. cancer tissues, and in dif-
ferent histological subtypes.
To identify PcG targets inactivated in brain tumors,
we interrogated the following Oncomine categories:
“PcG target genes in human embryonic SCs” and “Top
10% downregulated genes in glioblastoma (Sun Brain)”.
We found 106 overlapping genes. Since these genes
were identified by the intersection of data from genes
that are silenced by PRC2 in human embryonic SCs and
from glioblastoma studies, these 106 overlapping genes
will be hereinafter called “PRC2 targets in brain
tumors”.
To identify genes expressed in association with EZH2,
coexpression data from 3 large studies (Beroukhim, Phil-
lips, Sun, 467 patients) were collected. We found 213
genes positively correlated to EZH2 (R > 0.70). These
genes will be called “EZH2-associated genes”.
All statistical values relative to this meta-analysis were
calculated as described by Chinnaiyan and colleagues
[20].
Table 1 summarizes differentially expressed PcG genes
in normal brain, brain tumors and specific tumor histolo-
gies. Surprisingly, some PRC1 components (BMI1, CBX2,
CBX7) were downreglated in glioblastoma compared to
normal brain. Other PRC1 members (CBX7, PCGF6)
were selectively expressed in lower grade gliomas. In con-
trast, the PRC2 components EZH2 and SUZ12 were
always overexpressed in tumors compared to normal
neural tissue. In addition, these 3 independent studies all
showed a highly significant correlation between EZH2
overexpression and gliomas. Moreover, EZH2 expression
significantly increased with tumor grade in both adult
and pediatric brain tumors (Figure 1A, B).
These results show that PRC2 genes may play a cru-
cial role in adult and pediatric brain tumors. BMI1
mRNA expression seems not to predict tumor progres-
sion. This seems to be in contrast with previous evi-
dence [16], showing that BMI1 protein sustains
glioblastoma CSC self-renewal. However, BMI1 protein
and mRNA levels may not be directly correlated, and
many post-transcriptional modulations may explain this
discrepancy.
Table 1 Polycomb genes expression in normal brain and specific tumor histologies.
PRC GENE Category 1
(up-regulated)
Category 2
(down- regulated)
P value
1 BMI1 Normal Brain Glioblastoma 5.85 E-27
CBX2 Neural Stem Cell Glioblastoma 4.4 E-13
CBX7 Normal Brain Glioblastoma 2.2 E-27
Ganglioneur-oma/-oblastoma Neuroblastoma 2.4 E-7
PCGF1 Glioblastoma Astrocytoma 1.2 E-6
PCGF6 Astrocytoma/Oligodendroglioma Glioblastoma 4.0 E-6
PHC2 Astrocytoma/Glioblastoma Oligodendroglioma 1.4 E-7
YY1 Anaplastic Oligoastrocytoma Normal Brain 1.23 E-5
Medulloblastoma with Advanced Neural Differentiation Other hystologies 8.86 E-27
Oligodendroglioma Mixed Glioma 3.83 E-6
2, 3, 4 EZH2 Anaplastic Oligodendroglioma Normal Brain 1,12E-12
Anaplastic Astrocytoma Normal Brain 3,50E-13
Glioblastoma Normal Brain 2,56E-23
Neuroblastoma Ganglioneur-oma/-oblastoma 4,94E-08
Glioblastoma Astrocytoma/Ogligodendroglioma 1.64 E-5
RBBP7 Anaplastic Astrocytoma Normal Brain 6,0E-06
Anaplastic Oligodenroglioma Normal Brain 5,60E-08
SUZ 12 Anaplastic Oligodendroglioma Normal Brain 1.19 E-7
Atypical Theratoid/Rhabdoid Tumor Medulloblastoma 5.50 E-8
4 SIRT1 Neural Stem Cell Glioblastoma 9.4 E-13
Oligodendroglioma Glioblastoma Astrocytoma 1.9 E-11
Data derived from Oncomine database. Grading analyses were performed on 35 adult and 19 pediatric brain tumors. Survival analysis was performed on a total
of 97 glioblastoma patients.
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Since EZH2 is essential for NCSC self-renewal [12],
and due to our results showing that EZH2 is overex-
pressed in brain tumors, we investigated the prognostic
role of EZH2 in gliobalstoma. Two independent studies
showed a highly significant association between EZH2
overexpression and poorer 1 year- and 3 year-survival in
glioblastoma patients (Figure 1C, D). We identified a
significant and progressive (p = 4.4E-7, odds ratio = 2.0)
pattern of PRC2 target gene silencing in gliomas (Figure
2A). In addition, a list of 52 PRC2 targets was downre-
gulated in poor prognosis-glioblastoma patients, and
predicted shorter 3-year survival (p = 4.2E-6, odds ratio
= 2.2, additional file 1).
Our analysis suggests that glioma progression is asso-
ciated with EZH2 overexpression and PRC2 target gene
silencing. Thus, we investigated which pathways are co-
activated with EZH2, and which pathways are silenced
by PRC2. For these purposes, we compared two sets of
genes: PRC2 targets in glioma and EZH2-associated
genes. The latter category includes 213 genes positively
correlated with EZH2, identified in three large microar-
ray studies in brain tumors. Ingenuity pathway analysis
(IPA, Ingenuity® Systems, http://www.ingenuity.com of
EZH2-associated genes showed the following top cate-
gories: “Cancer” (4.6E-14<p < 1.5E-2), “Cell cycle”
(6.02E-31<p < 1.5E-2) and “Embryonic development”
(2.3E-5<p < 1.5E-2). Interestingly, when we compared
IPA for both EZH2-associated genes and PRC2 targets
in brain tumors, we found that the first gene set was
significantly enriched for Cell-cycle- Cancer-, and Cellu-
lar movement-associated genes, compared to PRC2 tar-
gets (Figure 2B). Gene categories significantly enriched
in PRC2 target genes included: “Behavior”, “Neurological
disorders” and “Psychological disorders”. Our analysis
suggests that PRC2 specifically silences genes involved
in mature brain functions, and that EZH2 is overex-
pressed in undifferentiated cells.
In addition, EZH2 may indirectly activate cell cycle
progression, tumorigenesis and invasion, as shown in
other cancer types [5]. In this regard, the top canonical
pathway activated in EZH2-associated genes was “Mito-
tic roles of Polo-like kinases” (p = 1.83E-11). As shown
in Figure 3, several EZH2-associated genes are involved
in this pathway, which regulates mitotic entry and DNA
damage-activated checkpoints. Interestingly, Polo
kinases orchestrate the self-renewal versus
Figure 1 EZH2 expression in neurological tumors. A, B: EZH2 is overexpressed in higher grade tumors. C, D: EZH2 overexpression is
associated to poor prognosis in human glioblastoma (Oncomine database).
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differentiation decision in neural progenitors, by regulat-
ing the orientation of mitotic spindles [21]. Additional
pathways significantly associated with EZH2 expression
in glioma were “ATM signaling” (p = 2.2E-6), “G2/M
DNA damage checkpoint” (p = 1.0E-5) and “Sonic
hedgehog signaling” (p = 1.5E-3). ATM signaling is
involved in DNA repair, while Hedgehog pathway is
essential for neural SCs [5]. Our results are in agree-
ment with in vitro findings, showing that EZH2 is
required for cell cycle control and SC self-renewal [5].
To corroborate our findings, we uploaded PRC2 target
genes and EZH2-associated genes on the Broad Insti-
tute’s Molecular Signature Database http://www.broad-
institute.org/gsea/msigdb/annotate.jsp, and compared
significant overlaps with gene ontology signatures.
EZH2-associated genes were significantly correlated
with “Spindle” (p = 7.6E-15) and “Mitotic cell-cycle”
(p = 8.6E-15). These categories resembled IPA “Cell
Cycle” sub-categories correlated to EZH2: “Spindle
Checkpoint” (p = 5.3E-11) and “M-phase of eukaryotic
cells” (p = 1.2E-15). PRC2 target genes were associated
to “Trasmission of nerve impulse” (p = 9.1E-5) and
“Axonogenesis” (p = 1.6E-4). These results corroborate
the hypothesis that PRC2 inhibits neural differentiation-
associated genes in human brain tumors. In addition,
they confirmed the likelihood of a relationship between
EZH2 and mitotic control. Interestingly, EZH2-asso-
ciated genes were also significantly linked to “Up-regu-
lated in doxorubicine resistant cells” (p = 2.2E-36). This
again highlights the probability of an association
between EZH2 expression and NCSCs, since these are
the cells thought to be responsible for chemotherapeutic
resistance.
In conclusion, we found a correlation between PRC2-
mediated gene silencing and brain tumor progression.
In particular, EZH2 predicts poor prognosis higher
grade. Network analysis revealed that brain tumor cells
overexpressing EZH2 display activation of SC- and cell
cycle-specific pathways, and consistent with this data,
differentiation genes are silenced by PRC2. Our results
obtained on patient gene expression profiles corrobo-
rate in vitro findings, showing that PRC2 is required
for NCSC self-renewal and for glioblastoma tumori-
genesis [12]. Interestingly, 3-dezaneplanocin A
(DZNeP) was shown to disrupt PRC2 activity, thereby
targeting NCSC tumorigenicity [12].. Our findings
Figure 2 Polycomb-related gene expression in glioblastomas. A: PRC2 target genes are selectively silenced in glioblastomas (Oncomine
database). B: Functional analysis comparing EZH2-associated genes (upper column, dark blue) with Polycomb targets (lower column, light blue)
in glioblastomas (IPA software).
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suggest that PRC2 is a viable target for human glioma
and possibly for other neurological tumors. Indeed, we
found that EZH2 expression progressively increases
with pediatric tumor grade (figure 1B). Finally, we
identified pathways associated with EZH2 expression
in brain tumors. Along with classical cell cycle and SC
pathways, we found a correlation between EZH2 and
polo-like kinases. Since polo kinases orchestrate sym-
metric division in neural SC [21], this new link is
potentially informative. Polo-like kinase 1 is overex-
pressed in human gliomas [22], and specific inhibitors
of these kinases are being investigated as anticancer
agents [23]. Thus, our results can pave the way to the
rational development of treatments that specifically
target NCSC. These drug regimens may include PRC2
and polo-like kinase inhibitors.
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Additional file 1: List of 52 PRC2 targets that are down-regulated in
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